Frequent Versus Infrequent Bathing in Pediatric Atopic Dermatitis: A Randomized Clinical Trial

Publication date: Available online 13 November 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Dr. Ivan D. Cardona, Dr. Erin E. Kempe, Dr. Christine Lary, Ms. Julia H. Ginder, Dr. Neal JainAbstractBackgroundStudies evaluating bathing frequency in pediatric atopic dermatitis (AD) are limited. Parents of children with AD often receive conflicting information, leading to frustration and confusion.ObjectiveTo evaluate efficacy of twice-daily, soaking baths, followed by immediate application of an occlusive moisturizer (i.e. soak-and-seal [SS]), versus twice-weekly SS baths, in the acute management of pediatric AD.MethodsWe conducted a randomized, single-blind, crossover-controlled trial comparing frequent versus infrequent SS baths, in children 6 months to 11 years of age with moderate-to-severe AD. Children were randomized 1:1 into 2 groups: Group 1 underwent twice-weekly SS baths, for 10-minutes or less, over 2-weeks (“dry method” - DM) followed by twice-daily SS baths, for 15-20 minutes, over 2-weeks (“wet method” - WM). Group 2 did the inverse. Patients received the same moisturizer, cleanser, and low-potency topical corticosteroid (TCS). Primary outcome was AD severity evaluated using SCORing Atopic Dermatitis (SCORAD) index. Caregiver assessment of AD severity (Atopic Dermatitis Quickscore – ADQ), quality of life, Staphylococcal aureus colonization, skin hydration, moisturizer and TCS usage were assessed.Result...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research

Related Links:

Objective: to evaluate the clinical efficacy and safety of long-term anti-IgE therapy patients with severe uncontrolled asthma.Materials and Methods: in Chelyabinsk city from November 2016 35 patients regularly receive omalizumab therapy - 9 men (26%) and 26 women (74%), the average age 44.5±14.1 years, the duration of asthma - 25.2±11.5 years. All patients had allergic pathology: allergic rhinitis - 100%, pollinosis - 79.4%, food allergy - 44.1%, atopic dermatitis - 26.5%. The level of total IgE in the blood is from 72 to 787 IU/ml, high sesitization to household (88.6%), epidermal (62.9%), pollen (74.3%) al...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Airway pharmacology and treatment Source Type: research
The immediate priority for clinicians managing patients with atopic dermatitis (AD) is treating the disease, particularly the constant itch and sleep disturbance, with its consequential disruption of both home and work life and association with low mood, poorer concentration, and productivity. However, long-term sequelae are important to consider and include those directly related to the atopic march (asthma, allergic rhinoconjunctivitis, and food allergies), the consequences of having a chronic disease, and potential side effects of therapy, particularly topical corticosteroids.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: Editorial Source Type: research
Atopic Dermatitis (AD) is a common condition often treated with topical corticosteroids. We developed an EMR-based tool to detect and monitor side effects and interventions in our atopic dermatitis population.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Skin Disorders Source Type: research
There is an increasing incidence of allergic contact dermatitis to corticosteroids. However, this diagnosis is being undetected or misdiagnosed, since topical corticosteroids are the first line treatment for inflammatory skin disorders.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
This study evaluated nemolizumab plus topical corticosteroids in patients with AD and severe pruritus and found a significant effect on cutaneous signs of AD (by EASI and IGA), plus a rapid reduction of pruritus.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
AbstractThe use of biologic agents as therapies for atopic diseases such as asthma and atopic dermatitis has increased greatly in recent years. The biological agents used to treat atopic diseases are for the most part monoclonal antibodies that suppress the immune response and reduce inflammation by targeting particular cytokines or other molecules involved in Th1, Th2, or Th17 immune reactions. Various side effects and rare complications have been reported from these agents. In this review, we discuss mechanisms of various adverse effects for the biologic agents currently in use or in development for atopic and inflammato...
Source: Clinical Reviews in Allergy and Immunology - Category: Allergy & Immunology Source Type: research
Endolysin treatment against Staphylococcus aureus in this randomized vehicle-controlled trial was well tolerated, but had no topical corticosteroid sparing effect in patients with atopic dermatitis. The effective run-in with corticosteroids may have influenced the results.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
Conclusion: These guidelines should form a reference for the management of patients with AD in an evidence-based manner.
Source: Indian Journal of Dermatology - Category: Dermatology Authors: Source Type: research
Discussion Sarcoidosis is rare and is even rarer in the pediatric age group. Sarcoidosis is seen in all ages with an estimated prevalence is 10-40/100,000 in the U.S. population. Pediatric sarcoidosis has an estimated incidence of 0.2/100,000 per year. For the pediatric age range it is more likely from 9-15 years of age. In adults it commonly presents between 20-39 years but bimodal distribution is also reported. Women are more likely to have sarcoidosis than men. African American females have the highest risk, and usually present slightly older, especially in the 4th decade of life. African American women are also more li...
Source: - Category: Pediatrics Authors: Tags: Uncategorized Source Type: news
Conclusions The clinical trials discussed here, which include several trials investigating novel therapeutic targets, demonstrate that translational research in pemphigus and pemphigoid is a fast-growing field. We thus expect that several novel treatments will be shortly available for the treatment of pemphigus and pemphigoid patients. Given the high, and thus far unmet, medical need in this field (110), this is highly encouraging and will hopefully improve the quality of life of the affected patients. In addition to the compounds and targets described here, several new targets have been recently identified in preclinical...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Allergy | Allergy & Immunology | Children | Clinical Trials | Corticosteroid Therapy | Dermatitis | Dermatology | Eyes | Pediatrics | Skin | Study